He Ying, Das Bikul, Baruchel Sylvain, Kumar Piyush, Wiebe Leonard, Reilly Raymond M
Division of Nuclear Medicine, University Health Network, Toronto, Canada.
Nucl Med Commun. 2004 Nov;25(11):1125-30. doi: 10.1097/00006231-200411000-00010.
The Auger electron-emitting agents meta-[125I]iodobenzylguanidine (125I-MIBG) and 123I-MIBG have been proposed as alternatives to 131I-MIBG for the treatment of neuroblastoma, due to the absence of a cross-fire effect which may minimize bone marrow toxicity. However, the differential toxicity of 123I-MIBG towards neuroblastoma cells and cells of haematopoietic lineage has not been studied.
To compare the toxic effects of 123I-MIBG on SK-N-SH and SK-N-BE(2) neuroblastoma cells and on cells of haematopoietic lineage, specifically HL-60 human myeloid leukemia cells and bone marrow stem cells (BMSCs) from human adult donors.
The antiproliferative effects of exchange-labelled or no carrier added (n.c.a.) 123I-MIBG, unlabelled MIBG or the trimethylsilylbenzylguanidine (MTBG) precursor used to prepare n.c.a. 123I-MIBG against SK-N-SH or SK-N-BE(2) cells or HL-60 cells were evaluated using a cell proliferation assay. The toxicity of 123I-MIBG towards SK-N-SH cells or BMSCs from healthy adult human donors was studied using a clonogenic assay.
123I-MIBG was strongly growth inhibitory to SK-N-SH or SK-N-BE(2) cells at concentrations (IC50 185-370 mBq.ml(-1); IC90 740 mBq.ml(-1)) that were sparing to HL-60 cells. Treatment of SK-N-SH cells with 74 mBq of 123I-MIBG decreased colony formation by >90%, whereas colonies from all three populations of stem cells were formed at amounts up to 370 mBq. It was discovered that the MTBG precursor was non-specifically toxic towards both SK-N-SH cells and HL-60 cells, suggesting the need to purify n.c.a. 123I-MIBG for clinical use.
Our results suggest that 123I-MIBG is a promising novel radiotherapeutic agent for neuroblastoma. For the first time, we report that the MTBG precursor used to prepare n.c.a. 123I-MIBG was toxic towards neuroblastoma cells as well as to HL-60 cells, representing cells of the haematopoietic lineage, suggesting the need for purification.
由于不存在可能使骨髓毒性最小化的交叉火力效应,已提出俄歇电子发射剂间位-[¹²⁵I]碘苄胍(¹²⁵I-MIBG)和¹²³I-MIBG作为¹³¹I-MIBG治疗神经母细胞瘤的替代物。然而,尚未研究¹²³I-MIBG对神经母细胞瘤细胞和造血谱系细胞的差异毒性。
比较¹²³I-MIBG对SK-N-SH和SK-N-BE(2)神经母细胞瘤细胞以及造血谱系细胞(特别是HL-60人髓系白血病细胞和来自成年供体的人骨髓干细胞(BMSC))的毒性作用。
使用细胞增殖试验评估交换标记或无载体添加(n.c.a.)的¹²³I-MIBG、未标记的MIBG或用于制备n.c.a.¹²³I-MIBG的三甲基硅基苄胍(MTBG)前体对SK-N-SH或SK-N-BE(2)细胞或HL-60细胞的抗增殖作用。使用克隆形成试验研究¹²³I-MIBG对来自健康成年人类供体的SK-N-SH细胞或BMSC的毒性。
¹²³I-MIBG在对HL-60细胞无损害的浓度(IC₅₀ 185 - 370 mBq·ml⁻¹;IC₉₀ 740 mBq·ml⁻¹)下对SK-N-SH或SK-N-BE(2)细胞具有强烈的生长抑制作用。用74 mBq的¹²³I-MIBG处理SK-N-SH细胞可使集落形成减少>90%,而在高达370 mBq的剂量下所有三种干细胞群体均能形成集落。发现MTBG前体对SK-N-SH细胞和HL-60细胞均具有非特异性毒性,这表明临床使用时需要纯化n.c.a.¹²³I-MIBG。
我们的结果表明¹²³I-MIBG是一种有前景的新型神经母细胞瘤放射治疗剂。我们首次报告,用于制备n.c.a.¹²³I-MIBG的MTBG前体对神经母细胞瘤细胞以及对代表造血谱系细胞的HL-60细胞有毒性,这表明需要进行纯化。